Completed PHASE3 INTERVENTIONAL NCT00001038

A Study of Valacyclovir Hydrochloride in the Prevention of Life-Threatening Cytomegalovirus Disease in HIV-Infected Patients

A Randomized, Double-Blind Trial of Valacyclovir Hydrochloride (BW 256U87) Prophylaxis for Opportunistic Cytomegalovirus End-Organ Disease in Patients With Advanced HIV Infection (< 100 CD4+ Lymphocytes)

Sponsor: Glaxo Wellcome

Conditions Cytomegalovirus Infections HIV Infections

Interventions Acyclovir Valacyclovir hydrochloride

Updated 6 times since 2017 Last updated: Feb 28, 2011 Primary completion: May 31, 1996

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Cytomegalovirus Infections and HIV Infections and is currently completed. Glaxo Wellcome leads this study, which shows 6 recorded versions since 2026 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Glaxo Wellcome
National Institute of Allergy and Infectious Diseases (NIAID)

Data source: National Institute of Allergy and Infectious Diseases (NIAID)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Baltimore, United States , Berlin, Germany , Bern, Switzerland , Birmingham, United States , Boston, United States , Calgary, Canada , Chapel Hill, United States , Chicago, United States , Columbus, United States , Denver, United States and 20 more locations